Business Description
Qingdao Haier Biomedical Co Ltd
ISIN : CNE100003P25
Share Class Description:
SHSE:688139: Class ACompare
Compare
Traded in other countries / regions
688139.China IPO Date
2019-10-25Description
Qingdao Haier Biomedical Co Ltd is engaged in designing, manufacturing, marketing and sales of low temperature storage equipment for biomedical samples. The company provides provides complete storage solutions for biological sample banks, blood safety, vaccine safety, medical supplies and reagent safety.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 40.87 | |||||
| Equity-to-Asset | 0.76 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.12 | |||||
| Interest Coverage | 105.7 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 7.26 | |||||
| Beneish M-Score | -1.7 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 18.6 | |||||
| 3-Year EBITDA Growth Rate | 7.5 | |||||
| 3-Year EPS without NRI Growth Rate | 3 | |||||
| 3-Year FCF Growth Rate | -50.5 | |||||
| 3-Year Book Growth Rate | 15 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 44.84 | |||||
| 9-Day RSI | 47.25 | |||||
| 14-Day RSI | 50.09 | |||||
| 6-1 Month Momentum % | -14.23 | |||||
| 12-1 Month Momentum % | -17.09 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.8 | |||||
| Quick Ratio | 2.53 | |||||
| Cash Ratio | 1.95 | |||||
| Days Inventory | 78.77 | |||||
| Days Sales Outstanding | 52.55 | |||||
| Days Payable | 142.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.55 | |||||
| Dividend Payout Ratio | 0.44 | |||||
| 3-Year Dividend Growth Rate | 35.7 | |||||
| Forward Dividend Yield % | 1.55 | |||||
| 5-Year Yield-on-Cost % | 1.55 | |||||
| 3-Year Average Share Buyback Ratio | -0.1 | |||||
| Shareholder Yield % | 1.5 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 50.27 | |||||
| Operating Margin % | 14.83 | |||||
| Net Margin % | 16.01 | |||||
| FCF Margin % | 2.43 | |||||
| ROE % | 8.39 | |||||
| ROA % | 6.41 | |||||
| ROIC % | 10.16 | |||||
| ROC (Joel Greenblatt) % | 44.09 | |||||
| ROCE % | 8.37 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 29.45 | |||||
| Forward PE Ratio | 17.55 | |||||
| PE Ratio without NRI | 28.18 | |||||
| Price-to-Owner-Earnings | 51.2 | |||||
| PEG Ratio | 1.24 | |||||
| PS Ratio | 4.71 | |||||
| PB Ratio | 2.46 | |||||
| Price-to-Tangible-Book | 3.38 | |||||
| Price-to-Free-Cash-Flow | 190.17 | |||||
| Price-to-Operating-Cash-Flow | 53.59 | |||||
| EV-to-EBIT | 22.6 | |||||
| EV-to-EBITDA | 22.6 | |||||
| EV-to-Revenue | 3.92 | |||||
| EV-to-FCF | 161.79 | |||||
| Price-to-Projected-FCF | 1.55 | |||||
| Price-to-Peter-Lynch-Fair-Value | 3.55 | |||||
| Price-to-Graham-Number | 2.06 | |||||
| Price-to-Net-Current-Asset-Value | 8.02 | |||||
| Price-to-Net-Cash | 20.8 | |||||
| Earnings Yield (Greenblatt) % | 4.42 | |||||
| FCF Yield % | 0.51 | |||||
| Forward Rate of Return (Yacktman) % | 10.65 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Qingdao Haier Biomedical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 2,236.576 | ||
| EPS (TTM) (Â¥) | 1.13 | ||
| Beta | 1.56 | ||
| Volatility % | 66.89 | ||
| 14-Day RSI | 50.09 | ||
| 14-Day ATR (Â¥) | 1.605113 | ||
| 20-Day SMA (Â¥) | 34.1205 | ||
| 12-1 Month Momentum % | -17.09 | ||
| 52-Week Range (Â¥) | 23.96 - 44.6 | ||
| Shares Outstanding (Mil) | 317.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Qingdao Haier Biomedical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Qingdao Haier Biomedical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Qingdao Haier Biomedical Co Ltd Frequently Asked Questions
What is Qingdao Haier Biomedical Co Ltd(SHSE:688139)'s stock price today?
The current price of SHSE:688139 is ¥33.28. The 52 week high of SHSE:688139 is ¥44.60 and 52 week low is ¥23.96.
When is next earnings date of Qingdao Haier Biomedical Co Ltd(SHSE:688139)?
The next earnings date of Qingdao Haier Biomedical Co Ltd(SHSE:688139) is .
Does Qingdao Haier Biomedical Co Ltd(SHSE:688139) pay dividends? If so, how much?
The Dividend Yield %  of Qingdao Haier Biomedical Co Ltd(SHSE:688139) is 1.55% (As of Today), Highest Dividend Payout Ratio of Qingdao Haier Biomedical Co Ltd(SHSE:688139) was 0.44. The lowest was 0.19. And the median was 0.29. The  Forward Dividend Yield % of Qingdao Haier Biomedical Co Ltd(SHSE:688139) is 1.55%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers